Transaction · 0001628280-26-060962

Stengone Carmine N.

Stengone Carmine N., CEO, PRES, reported a transaction classified as exercise at Contineum Therapeutics, Inc. involving 2500.000000 shares for an estimated $2525.00. Reported holdings after the transaction were 19717.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MCEO, PRES
CTNMContineum Therapeutics, Inc.
Filing timeSep 08
Trade dateSep 08, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$16.85
Pre-filing
1mo ago -10.7%1w ago +0.0%1d ago +0.0%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

CTNM price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
CTNM since 2026-09-08Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001628280-26-060962
Class A Common Stock
Transaction date
Sep 08, 2026
Filed Sep 08, 2026, 10:08 PM · 0d delay
Shares
2.50k sh
$101 per share
Estimated value
$252k
Computed from shares × price
Holdings after
19.7k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO and President

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

  2. F2

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.59, inclusive. The reporting person undertakes to provi…

  3. F3

    Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.

Original filing · 0001628280-26-060962
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

CTNM